Christian Wichmann

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, Frankfurt, Germany
    Blood 116:603-13. 2010
  2. ncbi Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO
    Christian Wichmann
    Biomedical Research Institute Georg Speyer Haus, Paul Ehrlich Str 42 44, 60596 Frankfurt am Main, Germany
    Curr Drug Targets 11:1181-91. 2010
  3. ncbi Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, 60596 Frankfurt M, Germany
    Cancer Res 67:2280-9. 2007
  4. ncbi The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex
    Alexander B Maurer
    Georg Speyer Haus, Institute for Biomedical Research, Frankfurt am Main, Germany
    Blood 99:2647-52. 2002

Detail Information

Publications4

  1. ncbi Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, Frankfurt, Germany
    Blood 116:603-13. 2010
    ..Our data reveal the existence of an essential structural motif (hot spot) at the NHR2 dimer-tetramer interface, suitable for a molecular intervention in t(8;21) leukemias...
  2. ncbi Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO
    Christian Wichmann
    Biomedical Research Institute Georg Speyer Haus, Paul Ehrlich Str 42 44, 60596 Frankfurt am Main, Germany
    Curr Drug Targets 11:1181-91. 2010
    ..With a special focus on RUNX1/ETO we will discuss recent strategies to directly interfere with aberrant transcription factors to block their leukemogenic function...
  3. ncbi Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, 60596 Frankfurt M, Germany
    Cancer Res 67:2280-9. 2007
    ..Our results indicate that selective interference with the oligomerization domain of ETO could provide a promising strategy to inhibit the oncogenic properties of the leukemia-associated fusion protein RUNX1/ETO...
  4. ncbi The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex
    Alexander B Maurer
    Georg Speyer Haus, Institute for Biomedical Research, Frankfurt am Main, Germany
    Blood 99:2647-52. 2002
    ....